Trials / Approved For Marketing
Approved For MarketingNCT04125472
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),
Detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lumasiran | Lumasiran administered as a subcutaneous (SC) injection |
Timeline
- First posted
- 2019-10-14
- Last updated
- 2024-02-16
Source: ClinicalTrials.gov record NCT04125472. Inclusion in this directory is not an endorsement.